ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional

Combination Chemotherapy Followed By Peripheral Stem Cell Transplantation or Isotretinoin in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Acute Lymphocytic Leukemia

ClinicalTrials.gov ID: NCT00003619

Public ClinicalTrials.gov record NCT00003619. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 3, 2026, 11:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II Combination Study of Topotecan, Fludarabine, Cytosine Arabinoside and G-CSF (T-FLAG) Induction Therapy in Patients With Poor Prognosis AML, MDS and Relapsed/Refractory ALL Followed by Maintenance of Either PBSC Transplant or 13 Cis-Retinoic Acid

Study identification

NCT ID
NCT00003619
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Drexel University College of Medicine
Other
Enrollment
Not listed

Conditions and interventions

Interventions

  • bone marrow ablation with stem cell support Procedure
  • busulfan Drug
  • cytarabine Drug
  • etoposide Drug
  • filgrastim Biological
  • fludarabine phosphate Drug
  • isotretinoin Drug
  • peripheral blood stem cell transplantation Procedure
  • topotecan hydrochloride Drug
  • vitamin E Dietary Supplement

Procedure · Drug · Biological + 1 more

Eligibility (public fields only)

Age range
19 Years to 90 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 1998
Primary completion
Not listed
Completion
Mar 31, 2004
Last update posted
Jun 25, 2013

1998 – 2004

United States locations

U.S. sites
2
U.S. states
1
U.S. cities
1
Facility City State ZIP Site status
Medical College of Pennsylvania Hospital Philadelphia Pennsylvania 19129
Medical College of Pennsylvania Philadelphia Pennsylvania 19129

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00003619, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 25, 2013 · Synced May 3, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00003619 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →